Back to Search
Start Over
Weighing the Risks and Benefits of Neoadjuvant Therapy in Resectable Pancreatic Cancer: Early, Aggressive Neoadjuvant Therapy Is Appropriate in Selected Patients
- Source :
- Oncology. January, 2018, Vol. 32 Issue 1, p39, 4 p.
- Publication Year :
- 2018
-
Abstract
- The treatment of resectable pancreatic cancer--pancreatic ductal adenocarcinoma--involves surgical resection and adjuvant chemotherapy. The American Society of Clinical Oncology clinical practice guidelines recommend resection followed by treatment with gemcitabine and [...]
- Subjects :
- Pancreatic cancer -- Care and treatment
Neoadjuvant therapy -- Comparative analysis -- Methods -- Research
Adjuvant chemotherapy -- Comparative analysis -- Methods -- Research
Cancer research
Chemotherapy
Cancer treatment
Adenocarcinoma
Practice guidelines (Medicine)
Professional associations
Bevacizumab
Medical care quality
Health
Subjects
Details
- Language :
- English
- ISSN :
- 08909091
- Volume :
- 32
- Issue :
- 1
- Database :
- Gale General OneFile
- Journal :
- Oncology
- Publication Type :
- Periodical
- Accession number :
- edsgcl.575010692